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Abstract
Background: α-Galactosylceramide (α-GalCer) can be presented by CD1d molecules of antigen-
presenting cells, and is known to induce a potent NKT cell-dependent cytotoxic response against
tumor cells. However, the main effector cells in α-GalCer-induced antitumor immunity are still
controversial.
Methods: In order to elucidate the cell phenotype that plays the most important role in α-GalCer-
induced antitumor immunity, we purified and analyzed tumor-infiltrating leukocytes (TILs) from
liver metastatic nodules of a colon cancer cell line (Colon26), comparing α-GalCer- and control
vehicle-treated mice. Flow cytometry was performed to analyze cell phenotype in TILs and IFN-γ
ELISA was performed to detect antigen-specific immune response.
Results: Flow cytometry analysis showed a significantly higher infiltration of NK cells (DX5+, T
cell receptor αβ (TCR)-) into tumors in α-GalCer-treated mice compared to vehicle-treated mice.
The DX5+TCR+ cell population was not significantly different between these two groups,
indicating that these cells were not the main effector cells. Interestingly, the CD8+ T cell population
was increased in TILs of α-GalCer-treated mice, and the activation level of these cells based on
CD69 expression was higher than that in vehicle-treated mice. Moreover, the number of tumor-
infiltrating dendritic cells (DCs) was increased in α-GalCer-treated mice. IFN-γ ELISA showed
stronger antigen-specific response in TILs from α-GalCer-treated mice compared to those from
vehicle-treated mice, although the difference between these two groups was not significant.
Conclusions: In α-GalCer-induced antitumor immunity, NK cells seem to be some of the main
effector cells and both CD8+ T cells and DCs, which are related to acquired immunity, might also
play important roles in this antitumor immune response. These results suggest that α-GalCer has
a multifunctional role in modulation of the immune response.
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Background
Colorectal cancer is one of the most common neoplasms
worldwide. The mortality of this malignancy is closely
related to the existence of metastatic liver disease [1,2].
Many treatments, including chemotherapy and transcath-
eter arterial embolization, have been used to treat patients
with metastatic liver lesions of colorectal cancer, however,
the clinical outcome has not been satisfactory [2,3].
Therefore, a new treatment modality is necessary to
achieve a breakthrough in this area.
Recently, a specific glycolipid antigen, α-galactosylcera-
mide (α-GalCer), has been reported to induce significant
antitumor immunity in the mouse hepatic metastases
model [4-6]. α-GalCer can be presented by CD1d mole-
cules of antigen-presenting cells, and is known to induce
a potent natural killer T (NKT) cell-dependent cytotoxic
response against tumor cells [7-10]. Several reports have
indicated the direct cytotoxicity of NKT cells in murine in
vivo or in vitro models [6,7,11,12], which suggested that
NKT cells were the main effector cells in α-GalCer-
induced antitumor immunity. On the other hand, other
studies suggested that NK cells are the main cytotoxic
effectors in the liver of α-GalCer-treated mice [5,13-15].
Some reports [4,5] demonstrated that α-GalCer-induced
regression of hepatic metastases was related to marked
augmentation of the cytotoxicity of hepatic lymphocytes
against tumor cell lines in vitro, and the main effector cells
among the hepatic lymphocytes of the induced cytotoxic-
ity were NK cells, not NKT cells. In addition, they sug-
gested that CTLs specific to tumor cells were also
generated  in vivo in response to α-GalCer, since mice
cured of hepatic metastases upon treatment with α-Gal-
Cer acquired tumor-specific immunity. Our previous
study [16] also demonstrated that, among human hepatic
lymphocytes, Va24 NKT cells proliferated significantly in
response to α-GalCer, whereas the direct effector cells of
the elicited antitumor cytotoxicity in vitro were CD3-
CD56+ NK cells. The proliferating Vα24 NKT cells did not
exhibit any cytotoxicity against the K562 and Colo201 cell
lines. Eberl and MacDonald demonstrated that activated
NKT cells selectively induced NK cell proliferation and
cytotoxicity via an IFN-γ and IL-12-dependent pathway
[17]. Thus, NKT cells, activated by a specific CD1d-
restricted antigen, may induce innate immunity indirectly
via NK cells.
In this study, to elucidate the cell phenotype that plays the
major role in this α-GalCer-induced antitumor immunity,
we purified tumor-infiltrating leukocytes (TILs) from liver
metastatic nodules of mice 3 weeks after the intrasplenic
inoculation of colon cancer cells. The cell population con-
sisting of TILs was analyzed by flow cytometry and com-
pared between α-GalCer- and control Vehicle-treated
mice. CD8+ T cells and DCs as well as NK cells infiltrated
metastatic tumors more extensively in α-GalCer-treated
mice. Our results suggest that α-GalCer has a multifunc-
tional role in modulation of the immune response.
Methods
Mice
Female Balb/c mice were obtained from Japan SLC (Shi-
zuoka, Japan) and kept in a specific pathogen-free animal
facility in our university. They were used in experiments at
6 to 7 weeks of age. Groups of 9 mice were used in each
experiment. Experiments were repeated three times.
Antibodies
FITC-labeled anti-mouse CD3 (145-2C11), CD4 (GK1.5),
CD11c (HL3), CD69 (H1.2F3), anti-mouse αβ T cell
receptor (H57-597), and anti-I-Ad (AMS-32.1), and PE-
labeled anti-panNK cell (DX5), anti-CD8 (53-6.7), anti-
CD80 (16-10A1), and anti-B220 (RA3-6B2) monoclonal
antibodies were purchased from Becton-Pharmingen (San
Diego, CA).
Liver metastasis model of colorectal cancer in mice
Mice were anesthetized and the left flank was cut to open
the peritoneal cavity. After the spleen was pulled out, it
was inoculated with 2 × 105 Colon26 cells, followed by
splenectomy. The mice were allowed to recover for 6 days,
randomized and divided into two groups on day 7: alpha-
galactosylceramide (α-GalCer, kindly provided by Kirin
Brewery Co, LTD) treatment group and control treatment
(vehicle-treated) group. On days 7, 14, 17, and 20, mice
were injected intraperitoneally with 100 µg/kg (mouse
body weight) of α-GalCer or an equal amount of vehicle
(0.5% polysorbate 20 in 0.9% NaCl solution). On day 21,
mice were sacrificed and their livers were collected and
weighed. At this time, metastasis to other organs was also
examined.
Preparation of hepatic leukocytes and tumor-infiltrating 
leukocytes
Tumor nodules were carefully cut out from the livers mac-
roscopically and treated so as not to include adjacent nor-
mal liver parenchyma using a razor. Tumor nodules were
then inoculated with 1% of collagenase type IV solution
using 27G needles and then minced using scissors. Nod-
ules were then incubated at 37°C for 30 min, and a single-
cell suspension was obtained by pushing these incubated
tissue sections using the piston of a 10 ml syringe. Cell
suspensions were passed through a 100-gauge stainless
steel mesh to eliminate dead aggregated cells. Erythrocytes
were then lysed by treating them with NH4Cl buffer (0.15
M NH4Cl, 0.1 mM EDTA, 10 mM KHCO3). Hepatic leu-
kocytes (HLs) were collected using basically the same
methods. To separate leukocytes from tumor cells or
hepatocytes, cells were washed three times with PBS con-
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overlaid on Lympholyte M (1.0875; Cedarlane, Ontario,
Canada). Centrifugation was performed at 1,500 g for 30
min at room temperature. The interface fraction was col-
lected, and washed at least three times with PBS. Accord-
ing to the microscopic findings, almost all of
contaminating hepatocytes and tumor cells were spun
down to the high-density fraction. Finally, anti-CD45
MicroBeads (Miltenyi Biotec GmbH, Bergish Gladbach,
Germany) were added to the cells collected from the inter-
face fraction and leukocytes were positively selected using
MiniMACS (Miltenyi Biotec) according to manufacturer's
instructions. Collected leukocytes were analyzed by flow
cytometry.
Flow Cytometry
Approximately 1 million cells were suspended in 100 µl of
PBS/0.1%BSA/0.1% sodium azide and then incubated
with anti-FcR (Pharmingen) for 15 min at 4°C to prevent
nonspecific binding by mAb. The cells were then spun
down, resuspended in 100 µl of PBS/0.1%BSA/0.1%
sodium azide, and 2 µl of labeled Ab was added. After 30
min of incubation at 4°C, the suspension was washed two
times with PBS/0.1%BSA/0.1% sodium azide. Analysis
was performed using a FACSCalibur flow cytometer (Bec-
ton Dickinson, San Jose, CA). CellQuest software (Becton
Dickinson) was used for data analysis.
IFN-γ ELISA
TILs were suspended in 10% FCS-RPMI 1640 medium at
a density of 2 × 105 cells or 2 × 104 cells per 100 µl per well
in 96-well U-bottomed plates. Irradiated Colon26 tumor
cells or NIH3T3 cells were suspended at a density of 2 ×
105 cells/ml and 100 µl of suspension was added to each
well. Supernatants were harvested after 24 h of incubation
at 37°C, and tested for the IFN-γ concentration using an
ELISA kit (Genzyme, Cambridge, MA). Assays were per-
formed according to the manufacturer's instructions.
Statistical Analysis
Survival time was compared with the Kaplan-Meier
method, and significance was determined by the log-rank
test. Student's t-test was used to determine statistical sig-
nificance. Differences at P < 0.05 were considered statisti-
cally significant.
Results
Establishment of liver metastatic models of colon cancer 
cells
Balb/C mice were inoculated with tumor cells to deter-
mine the optimal conditions for mimicking liver metasta-
sis of colorectal cancer in humans. Liver metastasis of
colorectal cancer usually consisted of discrete nodular
lesions, rather than diffusely infiltrating lesions. The injec-
tion of more than one million cells into the spleen some-
times gave very diffuse metastatic lesions in the liver
without discrete nodules. However, when the spleen was
inoculated with 2 × 105 cells of cancer cells, liver metas-
tases were always discrete lesions that ranged in diameter
from 3 mm to 8 mm when the mice were sacrificed on day
14. When 4 × 104 or fewer tumor cells were injected, the
establishment of macroscopic metastasis on day 14 was
inconsistent. Therefore, we decided to inoculate 2 × 105
Colon26 cells to each mouse on day 0.
On day 7, mice were first treated with α-GalCer or vehicle.
The same treatment was repeated on day 14 and then once
every three days until death. Figure 1 shows the survival
curves of the α-GalCer-treated and control groups. These
two groups showed a statistically significant difference in
survival (p < 0.0001). The first death occurred on day 22
in the control group and on day 33 in the α-GalCer group.
All of the mice in the control group died within 31 days
after tumor inoculation. On the other hand, more than
half of the mice in the α-GalCer group was still alive on
day 37. However, perhaps due to the late start of α-GalCer
treatment after tumor inoculation, none of the mice sur-
vived after 55 days even in the α-GalCer-treated group.
Thus, we decided to sacrifice mice in both groups on day
21 to enucleate tumor nodules.
Survival in the Colon26 hepatic metastasis model Figure 1
Survival in the Colon26 hepatic metastasis model. 2 × 
105 Colon26 cells were injected into the spleen of each 
mouse on day 0. Colon26-bearing mice were randomly 
divided into an α-GalCer group and a control Vehicle group 
(9 mice per group). On day 7, day 14, and every 3 days there-
after, α-GalCer (100 µg/kg body weight) or control Vehicle 
(same volume as α-GalCer) was inoculated into the perito-
neal cavity, and survival was monitored daily until all of the 
mice had died. ❍ , Vehicle-treated mice; , α-GalCer-treated 
mice.
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Table 1 shows the liver weight and the number of tumor
nodules per mouse in both groups on day 21. Vehicle-
treated mice had significantly heavier livers than control
mice (p < 0.05) due to extensive metastasis, whereas there
was no significant difference between these mice and the
α-GalCer-treated group. On the other hand, there were
significantly fewer metastatic nodules in the α-GalCer
group than in the vehicle-treated group (p < 0.05). Perito-
neal tumor nodules were also found in three mice in the
vehicle-treated group, but not in the α-GalCer group.
These mice had slightly bloody ascites. No distant metas-
tasis was found in either group.
Comparison of cell populations comprising tumor-
infiltrating leukocytes
To obtain an adequate number of TILs for flow cytometry
analysis, tumor nodules obtained from three mice in the
same group were pooled and mixed into one sample.
Since both groups had nine mice, in each experiment flow
cytometry data were acquired in triplicate. Although this
difference was not statistically significant, there were more
TILs in the α-GalCer group (1.19 × 108 cells/g tumor tis-
sue) than in the control group (1.05 × 108 cells/g tumor
tissue).
Figure 2 shows the flow cytometry analysis of TILs and
HLs from α-GalCer-treated or vehicle-treated mice. The
percentages of DX5+ TCR- NK cells and DX5+ TCR+ NKT
cells among TILs were less than those in HLs in normal
liver parenchyma. The percentage of NK cells in TILs was
lower than that in HLs purified from control mice that
were not injected with tumor (α-GalCer-treated: 5.8 ±
0.7% vs. 8.0 ± 0.9%, vehicle-treated: 2.8 ± 0.3% vs. 9.4 ±
1.1%). However, NK cell infiltration into the tumors was
significantly enhanced by α-GalCer-treatment of mice
(5.8 ± 0.7% vs. 2.8 ± 0.3%). On the other hand, no signif-
icant increase in the DX5+ NKT cell population was found
in the tumors of α-GalCer-treated mice compared to Vehi-
cle-treated mice. Interestingly, the proportion of CD8+ T
cells in TIL was clearly enhanced in α-GalCer-treated mice
(11.7 ± 1.3%) compared to vehicle-treated mice (3.4 ±
0.3%). Accordingly, the CD8/CD4 ratio was higher in TIL
from α-GalCer-treated mice (ratio 0.40) than in that from
vehicle-treated mice (ratio 0.16). Moreover, CD69 expres-
sion was mildly enhanced on CD8+ T cells from α-Gal-
Cer-treated mice (33.3 ± 2.7% positive in CD8+
population) compared to those from vehicle-treated mice
(12.4 ± 1.6% positive in CD8+ population).
Interestingly, the DC population was significantly larger
in TILs of α-GalCer-treated mice than in those of vehicle-
treated mice (3.1 ± 0.7% vs. 1.4 ± 0.3%) (Figure 3). The
DC population in TILs was greater than that in corre-
sponding hepatic lymphocytes (α-GalCer-treated: 2.8 ±
0.7% vs. 0.4 ± 0.2%, vehicle-treated: 1.4 ± 0.3% vs. 1.2 ±
0.2%), suggesting the active infiltration of DCs into
tumors, especially in α-GalCer-treated mice. A compari-
son of CD11c/CD80 and I-A/B220 staining data indicated
that some of the tumor-infiltrating DCs in α-GalCer-
treated mice were CD80-negative, which suggested the
enhanced infiltration of immature DCs.
IFN-γ secretion by TILs
TILs purified from α-GalCer-treated and vehicle-treated
mice were cultured with 1 × 104 target cells for 24 h and
supernatants were collected for ELISA. Figure 4 shows the
IFN-γ secretion in each of 3 subgroups from α-GalCer-
and vehicle-treated mice. Although the amounts secreted
were low and no significant differences were observed
between the two groups (average at 10:1 of E:T ratio; α-
GalCer: 57.8 ± 10.0 pg/ml, Vehicle: 45.1 ± 4.9 pg/ml),
some of the pooled TIL samples from α-GalCer-treated
group showed slightly higher IFN-γ secretion when
Colon26 tumor cells were used as target cells. No IFN-γ
secretion was observed when control cells were used as a
target (average at 10:1 of E:T ratio; α-GalCer: 20.0 ± 3.2
pg/ml, Vehicle: 19.5 ± 3.7 pg/ml).
Discussion
α-GalCer can elicit a very strong antitumor immune
response in many tumor models of mice. Recent studies
have demonstrated that IFN-γ secreted by α-GalCer-acti-
vated NKT cells can activate NK cells, resulting in
enhanced antitumor immunity [13,15,18]. Several
murine models have shown that NKT cell-deficient mice
or NK cell-depleted mice have decreased or diminished
antitumor immunity [19,20]. On the other hand, some
studies have suggested that tumor-specific T cells are
Table 1: Liver weight and number of metastatic nodules.
vehicle αGalCer cont (vehicle) cont (αGalCer)
Liver Weight (g) 1.55 ± 0.21* 1.39 ± 0.14 1.23 ± 0.02* 1.25 ± 0.03
Number of Metastatic Nodules 17.6 ± 9.2** 8.3 ± 5.8** - -
2 × 105 colon26 cells were inoculated to spleens. On days 7, 14, 17, and 20, 100 µg/kg body weight of α-GalCer or an equal amount of vehicle was 
injected intraperitoneally into mice. On day 21, mice were sacrificed and liver weight was measured individually. Livers from sham operated mice 
without tumor inoculation were also measured as control. Metastatic nodules exposing liver surface were counted. *,**: p < 0.05.Journal of Immune Based Therapies and Vaccines 2004, 2:7 http://www.jibtherapies.com/content/2/1/7
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involved in the shrinkage or rejection of tumors [5,21,22].
Therefore, the collaboration of several cell types seems to
be important for the anti-metastatic effect of α-galactosyl-
ceramide.
To investigate how innate and adoptive immunity work in
the α-GalCer-induced antitumor immune response, espe-
cially at the site of liver metastasis of colorectal cancer, we
used a well-established murine colon cancer cell line,
Colon26, in Balb/C mice. We first tried to establish a
C57BL/6 mice model with the syngeneic MC38 colon can-
cer cell line [23] using the NK1.1 molecule as a NKT cell
marker. However, it was hard to determine the optimal
conditions to achieve constant numbers of discrete nod-
ules, since MC38 cells sometimes showed diffuse invasive
Flow cytometry analysis of tumor-infiltrating cells (I) Figure 2
Flow cytometry analysis of tumor-infiltrating cells (I). Leukocytes were isolated from liver parenchyma or metastatic 
liver tumors as described in the Materials and Methods. After incubation with anti-FcR antibody, cells were stained with pairs 
of FITC- and PE-labeled antibodies to analyze lymphocyte populations. The following combinations were used; FL1/FL2: αβ 
TCR/panNK (DX5), CD4/CD8, and CD69/CD8. Average percentages of each quadrant, calculated from three samples, are 
indicated. Underlined numbers in the CD4/CD8 dot plots show the CD8/CD4 ratio. The histograms show CD69 expression 
on CD8+ T cells and the percentages of CD69+ cells among CD8+ T cells are indicated. Representative data of three experi-
ments are shown. TIL: tumor-infiltrating leukocyte, HL: hepatic leukocyte.
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Flow cytometry analysis of tumor-infiltrating cells (II) Figure 3
Flow cytometry analysis of tumor-infiltrating cells (II). Leukocytes isolated from liver parenchyma or metastatic liver 
tumors were stained with pairs of FITC- and PE-labeled antibodies to analyze the DC population. After incubation with anti-
FcR antibody, cells were stained with the following antibody combinations. FL1/FL2: CD11c/CD80, and I-A/B220. The numbers 
in each dot plot show the average percentages of the quadrant calculated from three samples. Representative data of three 
experiments are shown. TIL: tumor-infiltrating leukocyte, HL: hepatic leukocyte.
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metastasis to the liver. Thus, we chose the Colon26 liver
metastasis model in Balb/C mice for this study.
Although Balb/C mouse strain does not express NK1.1
antigen [24,25], recent reports have demonstrated that a
panNK cell marker, DX5 antigen, can be a marker of NKT
cells in NK1.1 allelic negative mice [26,27]. According to
our results, the DX5+ TCR+ NKT cell population in TILs
did not increase by α-GalCer treatment (Fig. 2). However,
it is becoming clear that the NKT cell population consists
of several subpopulations [28], and therefore, our flow
cytometry data may not exclude the involvement of DX5-
NKT cells in this antitumor immunity. Our data demon-
strate that NK cells are some of the main effector cells in
our system, since there was a significant increase in the
DX5+TCR- NK cell population in α-GalCer-treated mice
(Fig. 2). Correspondingly, Kobayashi et al. [4] and Naka-
gawa et al. [5] demonstrated, using a hepatic metastasis
model, that the administration of α-GalCer to mice
enhanced the cytotoxicity of HLs against tumor cell lines
in vitro, and showed that the main effector cells among
HLs were NK cells, not NKT cells. Our previous study [16]
also demonstrated that, among human HLs, Vα24 NKT
cells proliferated significantly in response to α-GalCer,
whereas the direct effector cells of the induced antitumor
cytotoxicity in vitro were CD3-CD56+ NK cells.
On the other hand, the finding that the proportion of
tumor-infiltrating DCs increased is highly significant (Fig.
3), since this may indicate the subsequent establishment
IFN-γ secretion by tumor-infiltrating cells Figure 4
IFN-γ secretion by tumor-infiltrating cells. TILs purified from α-GalCer-treated and Vehicle-treated mice were cultured 
with 1 × 104 target cells for 24 h and supernatants were collected for IFN-γ ELISA. Each sample of α-GalCer-treated and Vehi-
cle-treated group is shown. Filled symbols: TILs from α-GalCer-treated mice, Open symbols: TILs from Vehicle-treated mice. 
Representative data of two experiments are shown.
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of acquired immunity. Clinically, an increased number of
tumor-infiltrating DCs has been reported to correlate with
a better prognosis in cancer patients [29,30]. Interestingly,
we observed a stronger infiltration of CD80-negative DCs
as well as CD80-positive DCs into tumors in α-GalCer-
treated mice than in vehicle-treated mice. An increased
number of immature DCs in tumors might reflect the
rapid infiltration of DCs from surrounding liver paren-
chyma, and these DCs might mature during antigen
processing. Since immature DCs have advantages for infil-
trating tumor nodules and taking up tumor antigens for T
cell priming, this finding may be related to a better prog-
nosis. Importantly, the proportion of CD8+ T cell infiltra-
tion increased from 3.6% to 10%, and the activation level
of these CD8+ T cells was upregulated in α-GalCer-treated
mice, based on the expression of an early activation
marker, CD69, on these cells (Fig. 2). These findings sug-
gest that cytotoxic T lymphocytes might play a significant
role as effector cells in this model. The establishment of an
antigen-specific T cell response has been suggested in
recent reports [4,5,21,22], since α-GalCer-injected mice
that had survived an initial tumor-cell challenge rejected
tumor growth after a second injection. In the present
study, we could not directly confirm the establishment of
tumor-specific immunity in vivo by a second inoculation
of tumor cells into surviving mice, since all of the mice,
including those in the α-GalCer-treated group, died, prob-
ably due to the late start of α-GalCer treatment in our
model.
An immunohistological analysis of tumor-infiltrating
cells has been reported using a liver metastasis model of
B16 melanoma in C57BL/6 mice [22], indicated increased
T cell infiltration as well as NK cell invasion into tumor
nodules. However, this analysis was not quantitative and
the functional properties of these TILs remained obscure.
We observed a slight increase in IFN-γ production by TILs
from α-GalCer-treated mice compared to TILs from con-
trol mice (Fig. 4), but this difference was not significant.
In the present study, TILs contained crude cell
populations and they were used for the assay soon after
isolation procedures without an incubation period for the
recovery of cell function. Therefore, IFN-γ ELISA might
not have been sensitive enough to see a tumor-specific
reaction in this assay condition. Further study is needed to
determine more detailed functional properties of TILs.
Conclusions
In this study, α-GalCer was shown to activate antitumor
immunity, and to enhance NK cell infiltration into tumor
nodules. This reagent may also elicit more profound
immunity, including acquired immunity, by inducing the
infiltration of DC and CD8+T cells into tumor nodules.
These findings suggest that this glycolipid antigen may be
a promising candidate for the treatment of cancer
patients.
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